{"id":3088,"date":"2023-09-26T22:37:34","date_gmt":"2023-09-26T20:37:34","guid":{"rendered":"https:\/\/blogs.sun.ac.za\/dttc\/?page_id=3088"},"modified":"2024-03-04T16:03:14","modified_gmt":"2024-03-04T14:03:14","slug":"benefit-kids-conferences","status":"publish","type":"page","link":"https:\/\/blogs.sun.ac.za\/dttc\/benefit-kids-conferences\/","title":{"rendered":"BENEFIT Kids | Conferences"},"content":{"rendered":"
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t2023 Union World Conference\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n<\/div><\/div>
\n
\n\t

The BENEFIT Kids Project, funded by Unitaid, aims to improve MDR-TB treatment for children, improving their health and reducing childhood deaths. We hosted a satellite session at the 53rd Union World Conference on Lung Health 2023 (November 15-18).<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div>

\n
\n\t

Click on the link below to read about the BENEFIT Kids Satellite Session<\/strong><\/p>\n

BENEFIT Kids Satellite Session<\/a><\/p>\n

\"\"<\/p>\n

 <\/p>\n

Important findings from the BENEFIT Kids Project had also been presented:<\/strong><\/p>\n

    \n
  1. The socio-economic impact of the COVID-19 pandemic in households having children with Rifampicin Resistant TB: Qualitative study from South Africa, India and Philippines.<\/li>\n
  2. Stigma in households of children with rifampicin-resistant tuberculosis in South Africa, India, and the Philippines.<\/li>\n
  3. Palatability preferences in children; the swish-and-spit taste panel approach for formulation development.<\/li>\n
  4. Pharmacokinetic-Toxicity Analysis of Long-term Linezolid Use in Children with MDR-TB.<\/li>\n
  5. Pharmacokinetics and optimal dosing of levofloxacin in children: An individual participant data meta-analysis.<\/li>\n<\/ol>\n

    \"\"<\/p>\n

    Click on the link below to access the BENEFIT Kids Post-Conference Toolkit<\/strong><\/p>\n

    Download Word Document<\/a><\/p>\n<\/div>\n<\/div><\/div>

    \n\t\t\t\t\t\t\t

    \n\t\t\t\t\t\t2022 Union World Conference\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t\t\t\t\t\t
    \n\t\t\t\t\t\t
    <\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n<\/div><\/div>
    \n
    \n\t

    In 2022, we presented important findings at the virtual Union World Conference on Lung Health 2022 (November 8-11) that were well-received:<\/span><\/p>\n<\/div>\n<\/div><\/div>

    \n
    \n\t
      \n
    1. Delamanid Tablets for Children:<\/strong> Dispersed 50mg delamanid tablets have the same effectiveness as whole tablets. This means they can be used in children and patients who can't swallow whole tablets, improving treatment accessibility.<\/li>\n
    2. Treatment Outcomes in Young Children:<\/strong> We conducted a global analysis of individual patient data to assess the impact of bedaquiline and delamanid on treatment outcomes in children under 3-6 years old with rifampicin-resistant tuberculosis. This helps us understand their effectiveness and safety in young children.<\/li>\n
    3. Predictors of Treatment Outcomes in Children:<\/strong> In our efforts to enhance the treatment of paediatric rifampicin-resistant tuberculosis (RR-TB), we conducted a comprehensive global review and individual patient data meta-analysis. This extensive study examined demographic, clinical, and treatment factors that influenced outcomes in 20,395 children and adolescents (0-19 years) receiving treatment for RR-TB.<\/li>\n
    4. Optimising Levofloxacin Formulations for Children:<\/strong> We conducted a crossover study comparing the pharmacokinetics of novel dispersible (paediatric) and standard non-dispersible (adult) levofloxacin formulations in children receiving routine preventive therapy for rifampicin-resistant tuberculosis. The study revealed differences in bioavailability and exposure between the formulations, prompting the development of new, optimised dosing strategies based on age and weight for globally available formulations.<\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div>
      \n
      \n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div>
      \n
      \n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

      The BENEFIT Kids Project, funded by Unitaid, aims to improve MDR-TB treatment for children, improving their health and reducing childhood deaths. We hosted a satellite session at the 53rd Union World Conference on Lung Health 2023 (November 15-18). Click on the link below to read about the BENEFIT Kids Satellite Session BENEFIT Kids Satellite Session […]<\/p>\n","protected":false},"author":12487,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-3088","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/pages\/3088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/users\/12487"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/comments?post=3088"}],"version-history":[{"count":24,"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/pages\/3088\/revisions"}],"predecessor-version":[{"id":3875,"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/pages\/3088\/revisions\/3875"}],"wp:attachment":[{"href":"https:\/\/blogs.sun.ac.za\/dttc\/wp-json\/wp\/v2\/media?parent=3088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}